2 recruiting, 1 active not recruiting, 1 suspended, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Suspended 1, Terminated 1 |
Follow Osteosarcoma in Children: new trials by email Literature Review of Osteosarcoma in Children trials Research Report on Osteosarcoma in Children
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma High-dose Methotrexate - Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults | Phase 2 | Recruiting | Wake Forest University Health Sciences | 46 | 2026-09-01 | 2026-10-13 |
| A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma OMO-103 - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Recruiting | Vall d'Hebron Institute of Oncology | 10 | 2024-12-27 | 2025-01-10 |
| Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma Cabozantinib, Best Supportive Care (BSC) - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Terminated | Ipsen | 10 | 2024-11-22 | 2026-10-29 |
| Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma Dinutuximab beta - Osteosarcoma in Children | Phase 2 | Suspended | Prof. Franca Fagioli | 22 | 2023-11-30 | 2023-11-18 |
| SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma Regorafenib 40 MG, Regorafenib 20MG, Nivolumab - Osteosarcoma, Osteosarcoma in Children | Phase 2 | Active not recruiting | Sarcoma Alliance for Research through Collaboration | 48 | 2021-06-04 | 2025-10-31 |
Osteosarcoma (4)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Bone Tissue (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Sarcoma (4)
Methotrexate (1) · Nivolumab (1) · cabozantinib (1) · dinutuximab (1) · regorafenib (1)
Ipsen (1) · Prof. Franca Fagioli (1) · Sarcoma Alliance for Research through Collaboration (1) · Vall d'Hebron Institute of Oncology (1) · Wake Forest University Health Sciences (1)
United States (3) · Italy (2) · Spain (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Franca Fagioli, MD (1) · Thomas Russell, MD (1)
2023 (1)